Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk index stratifies pediatric leukemia patients undergoing HSCT

Publish date:: June 8, 2020

Key clinical point: A validated disease risk index was developed for pediatric patients with acute myeloid or lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Major finding: For pediatric patients with very-high-risk acute myeloid leukemia, the 5-year probability of leukemia-free survival was 21%.

Study details: A risk modeling study involving 1,135 children with acute myeloid leukemia and 1,228 with acute lymphoblastic leukemia.

Disclosures: The study was funded by the National Institutes of Health. The investigators disclosed no conflicts of interest.

Citation:

Qayed M et al. ASCO 2020, Abstract 7503.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Hematology

Emotions, worse attention linked to pain-related health care use SCD,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds,

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability,

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders,